StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11−0.05 (-2.31%)

Close on Nov 17, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$170.39M. At the latest close the market valued the company at $231.62M.

Revenue
$0
TTM Q2 2026
Operating income
-$191.64M
TTM Q2 2026
Free cash flow
-$170.39M
TTM Q2 2026
EPS, diluted
-$0.17
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$231.62M
P/E ratio
–
Price to sales
–
Price to book
0.63
Dividend yield
–
Free cash flow yield
-73.56%

Fundamentals

Revenue
$0
Net income
-$17.25M
EPS, diluted
-$0.17
Free cash flow
-$170.39M
Book value per share
$3.22
Diluted shares
115M

Trading

Next earnings
Feb 25, 2027 (estimated, after the close)
Previous close
$2.16
Open
$2.16
Day's range
$2.03 – $2.19
Volume
1,785,209
Average volume (20 days)
1,645,095
Index membership
Russell 2000, Russell 3000
52-week range
$2.15 – $5.45
RSI (14 days)
37.0
Volatility (1 year)
68.7%
Relative volume
1.11×

On 1 of our idea list: More cash than they're worth

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2015, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodRCKTS&P 500DifferenceRCKT per yearS&P 500 per year
1 month-3.2%-4.0%+0.8 pts
3 months-37.9%-5.0%−33.0 pts
Year to date-39.9%+8.2%−48.1 pts
1 year-30.6%+11.2%−41.8 pts
3 years-90.4%+68.5%−158.9 pts-54.2%+19.0%
5 years-92.2%+67.3%−159.4 pts-39.9%+10.8%
10 years-91.9%+291.6%−383.5 pts-22.2%+14.6%

Thirteen years at a glance

Fiscal years 2013 to 2025 and trailing twelve months, USD

Revenue

$0

Operating income

-$191.64M

Net income

-$17.25M

EPS, diluted

-$0.17

Free cash flow

-$170.39M
Reported periodTrailing twelve months

Press releases

Releases Rocket Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Rocket Pharmaceuticals

Pharmaceutical Preparations

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing gene therapies for rare and life-threatening diseases. The company develops treatments using adeno-associated virus and lentiviral vector platforms to target conditions such as Danon disease, Fanconi anemia, pyruvate kinase deficiency, leukocyte adhesion deficiency-I, and cardiomyopathies. Its primary customers and end users include patients afflicted with severe genetic disorders, alongside the physicians, healthcare providers, and clinical institutions that treat these conditions.

Company profile, executives and history

Rocket Pharmaceuticals stock: common questions

What is Rocket Pharmaceuticals's stock price?

RCKT closed at $2.11 on Nov 17, 2026, down 2.31% on the day. Over the past 52 weeks it traded between $2.15 and $5.45.

What is Rocket Pharmaceuticals's market cap?

Rocket Pharmaceuticals was worth $231.62M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is RCKT's P/E ratio?

Rocket Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.17), so it has no meaningful P/E ratio.

How much revenue does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals reported revenue of $0 for the twelve months to Jun 30, 2026.

Does Rocket Pharmaceuticals pay a dividend?

No. Rocket Pharmaceuticals has not paid a cash dividend over the last twelve months.

When does Rocket Pharmaceuticals report earnings next?

Rocket Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has RCKT stock performed over the past year?

Including dividends, RCKT returned -30.6% over the past year, against +11.2% for the S&P 500.

How many RCKT shares are sold short?

16M shares were sold short at the latest FINRA report, 19.05% of the float, or 9.1 days of average trading volume.

Who are Rocket Pharmaceuticals's competitors?

Companies most similar to Rocket Pharmaceuticals by business, industry and size include SNGX, GRCE, RKTO, ABEO, NGNE.

See a number that looks wrong?